{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:54:11Z","timestamp":1790729651695,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2020.12.033","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T22:31:52Z","timestamp":1707085912000},"page":"242-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials"],"prefix":"10.1016","volume":"236","author":[{"given":"Vincent","family":"Muczynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit C.","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.thromres.2020.12.033_bb0005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/jth.12276","article-title":"An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B","volume":"11","author":"Rallapalli","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2020.12.033_bb0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0950-3536(11)80025-9","article-title":"Epidemiology of coagulation disorders","volume":"5","author":"Nathwani","year":"1992","journal-title":"Baillieres Clin. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2020.12.033_bb0015","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2006-10-050435","article-title":"Mortality rates, life expectancy, and causes of death in people with hemophilia a or B in the United Kingdom who were not infected with HIV","volume":"110","author":"Darby","year":"2007","journal-title":"Blood"},{"issue":"9371","key":"10.1016\/j.thromres.2020.12.033_bb0020","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias a and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"Suppl. 5","key":"10.1016\/j.thromres.2020.12.033_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13028","article-title":"Extended half-life clotting factor concentrates: results from published clinical trials","volume":"22","author":"Young","year":"2016","journal-title":"Haemophilia"},{"issue":"3685","key":"10.1016\/j.thromres.2020.12.033_bb0030","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.thromres.2020.12.033_bb0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/jvi.45.2.555-564.1983","article-title":"Nucleotide sequence and organization of the adeno-associated virus 2 genome","volume":"45","author":"Srivastava","year":"1983","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.thromres.2020.12.033_bb0040","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1001673107","article-title":"A viral assembly factor promotes AAV2 capsid formation in the nucleolus","volume":"107","author":"Sonntag","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.thromres.2020.12.033_bb0045","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/mr.54.3.316-329.1990","article-title":"Parvovirus replication","volume":"54","author":"Berns","year":"1990","journal-title":"Microbiol. Rev."},{"issue":"7","key":"10.1016\/j.thromres.2020.12.033_bb0050","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.gt.3300680","article-title":"Adeno-associated virus vectors can be efficiently produced without helper virus","volume":"5","author":"Matsushita","year":"1998","journal-title":"Gene Ther."},{"issue":"22","key":"10.1016\/j.thromres.2020.12.033_bb0055","doi-asserted-by":"crossref","first-page":"10613","DOI":"10.1073\/pnas.90.22.10613","article-title":"Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector","volume":"90","author":"Flotte","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.thromres.2020.12.033_bb0060","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/hum.1996.7.9-1145","article-title":"A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease","volume":"7","author":"Flotte","year":"1996","journal-title":"Hum. Gene Ther."},{"issue":"9117","key":"10.1016\/j.thromres.2020.12.033_bb0065","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S0140-6736(05)77740-0","article-title":"Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus","volume":"351","author":"Wagner","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.thromres.2020.12.033_bb0070","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.thromres.2020.12.033_bb0075","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2020.12.033_bb0080","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2020.12.033_bb0085","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.V97.5.1258","article-title":"Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA","volume":"97","author":"Nathwani","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2020.12.033_bb0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.thromres.2020.12.033_bb0095","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.thromres.2020.12.033_bb0100","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.thromres.2020.12.033_bb0105","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.thromres.2020.12.033_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"issue":"25","key":"10.1016\/j.thromres.2020.12.033_bb0115","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.12.033_bb0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.thromres.2020.12.033_bb0125","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.thromres.2020.12.033_bb0130","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2020.12.033_bb0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2020.12.033_bb0140","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.12.033_bb0145","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector Fidanacogene Elaparvovec and followed for at least 1 year","volume":"134","author":"George","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2020.12.033_bb0150","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.12.033_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced factor IX activity following administration of AAV5-R338L \u201cPadua\u201d factor IX versus AAV5 WT human factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"10.1016\/j.thromres.2020.12.033_bb0160","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2020.12.033_bb0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118050","article-title":"A single intravenous infusion of FLT180a results in factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with Haemophilia B","volume":"132","author":"Chowdary","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2020.12.033_bb0170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr. Gene Ther."},{"issue":"3","key":"10.1016\/j.thromres.2020.12.033_bb0175","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/mt.2015.151","article-title":"Genome engineering using adeno-associated virus: basic and clinical research applications","volume":"24","author":"Gaj","year":"2016","journal-title":"Mol. Ther."},{"issue":"7355","key":"10.1016\/j.thromres.2020.12.033_bb0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.thromres.2020.12.033_bb0185","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.thromres.2020.12.033_bb0190","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"85","key":"10.1016\/j.thromres.2020.12.033_bb0195","first-page":"379","article-title":"Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions","volume":"15","author":"Masat","year":"2013","journal-title":"Discov. Med."},{"issue":"3","key":"10.1016\/j.thromres.2020.12.033_bb0200","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.thromres.2020.12.033_bb0205","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.thromres.2020.12.033_bb0210","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.thromres.2020.12.033_bb0215","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by Immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.thromres.2020.12.033_bb0220","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"Mingozzi","year":"2013","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.thromres.2020.12.033_bb0225","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/gt.2011.64","article-title":"Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine","volume":"19","author":"McIntosh","year":"2012","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.thromres.2020.12.033_bb0230","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.thromres.2020.12.033_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2040620718791933","article-title":"Gene therapy for hemophilia: what does the future hold?","volume":"9","author":"Doshi","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.thromres.2020.12.033_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.thromres.2020.12.033_bb0245","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"Hosel","year":"2012","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.thromres.2020.12.033_bb0250","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2020.12.033_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell. Immunol."},{"issue":"10","key":"10.1016\/j.thromres.2020.12.033_bb0260","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.thromres.2020.12.033_bb0265","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"5837","key":"10.1016\/j.thromres.2020.12.033_bb0270","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.thromres.2020.12.033_bb0275","first-page":"134","article-title":"Long-term AAV-mediated factor VIII expression in nine hemophilia a dogs: a 10 year follow-up analysis on durability, safety and vector integration","author":"Nguyen","year":"2019","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:18:01Z","timestamp":1717251481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"alternative-id":["S0049384824000355"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.12.033","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}